UBS Knock-Out BAYN/ DE000UK0FJL8 /
5/21/2024 9:19:32 AM | Chg.+0.030 | Bid9:19:32 AM | Ask9:19:32 AM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
5.470EUR | +0.55% | 5.470 Bid Size: 150,000 |
5.480 Ask Size: 150,000 |
BAYER AG NA O.N. | 82.9673 EUR | 12/31/2078 | Put |
GlobeNewswire
5/20
Dupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS...
GlobeNewswire
5/20
Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ...
GlobeNewswire
5/2
AskBio Announces Nine Presentations at American Society of Gene and Cell Therapy 27th Annual Meeting...
GlobeNewswire
4/18
AskBio receives FDA Fast Track Designation for AB-1002 investigational gene therapy program in conge...
GlobeNewswire
4/16
AskBio presents 18-month Phase Ib trial results of AB-1005 gene therapy for patients with Parkinson’...
GlobeNewswire
4/11
Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from...
GlobeNewswire
3/25
BlueRock Therapeutics and Foundation Fighting Blindness announce collaboration to expand the Uni-Rar...
GlobeNewswire
3/6
BlueRock Therapeutics phase I clinical trial for Parkinson’s disease continues to show positive tren...
GlobeNewswire
3/4
BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM
GlobeNewswire
2/13
Corporate Alignment with Climate Goals Under Scrutiny: LyondellBasell & Bayer demonstrate good pract...
GlobeNewswire
2/13
First patient randomized in AskBio Phase II gene therapy trial for congestive heart failure
GlobeNewswire
1/5
AskBio Announces Initiation of Phase 2 GenePHIT Trial in Congestive Heart Failure (CHF)
GlobeNewswire
1/4
AskBio Phase Ib trial of AB-1005 gene therapy in patients with Parkinson’s disease meets primary end...
GlobeNewswire
12/14/2023
Iktos and Bayer Announce Collaboration to expand the use of Artificial Intelligence to Design New Su...